Prelude therapeutics announces second quarter 2021 financial results and operations update

- data from dose escalation portion of phase 1 trials of lead oral prmt5 inhibitors  prt543 and prt811 to be presented in 4q21 –
PRLD Ratings Summary
PRLD Quant Ranking